Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Spin-offs: Meet the structure specialists
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
Ustekinumab success in refractory Crohn’s disease
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
The Relative Importance of Baseline Pain, Fatigue, Sleep and Physical Activity: Predicting Change in Depression in Adults with Multiple Sclerosis.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons.
Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
B cells and multiple sclerosis.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Change in the clinical development program for laquinimod
Glatiramer acetate in the treatment of multiple sclerosis
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells.
The two faces of neuromyelitis optica.

Pages